Učitavanje...
Antiangiogenic therapy: impact on invasion, disease progression, and metastasis
Antiangiogenic drugs targeting the VEGF pathway have slowed metastatic disease progression in some patients, leading to progression-free survival (PFS) and overall survival benefits compared with controls. However, the results are more modest than predicted by most preclinical testing and benefits i...
Spremljeno u:
| Izdano u: | Nat Rev Clin Oncol |
|---|---|
| Glavni autori: | , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2011
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4540336/ https://ncbi.nlm.nih.gov/pubmed/21364524 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nrclinonc.2011.21 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|